
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7067753/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. New England Journal of Medicine, 2020, 382, 1564-1567.	13.9	7,369
2	SARS and MERS: recent insights into emerging coronaviruses. Nature Reviews Microbiology, 2016, 14, 523-534.	13.6	2,752
3	Airborne Transmission of Influenza A/H5N1 Virus Between Ferrets. Science, 2012, 336, 1534-1541.	6.0	1,416
4	A Novel Coronavirus Emerging in China — Key Questions for Impact Assessment. New England Journal of Medicine, 2020, 382, 692-694.	13.9	1,104
5	ChAdOx1ÂnCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. Nature, 2020, 586, 578-582.	13.7	840
6	The Global Phosphorylation Landscape of SARS-CoV-2 Infection. Cell, 2020, 182, 685-712.e19.	13.5	825
7	Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 6771-6776.	3.3	735
8	Animal models for COVID-19. Nature, 2020, 586, 509-515.	13.7	705
9	Respiratory disease in rhesus macaques inoculated with SARS-CoV-2. Nature, 2020, 585, 268-272.	13.7	619
10	Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer. Cell, 2020, 183, 1901-1912.e9.	13.5	618
11	Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2. Nature, 2020, 585, 273-276.	13.7	592
12	H5N1 Virus Attachment to Lower Respiratory Tract. Science, 2006, 312, 399-399.	6.0	573
13	Pathogenesis and Transmission of Swine-Origin 2009 A(H1N1) Influenza Virus in Ferrets. Science, 2009, 325, 481-483.	6.0	544
14	Human and Avian Influenza Viruses Target Different Cells in the Lower Respiratory Tract of Humans and Other Mammals. American Journal of Pathology, 2007, 171, 1215-1223.	1.9	473
15	Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV–infected rhesus macaques. Nature Medicine, 2013, 19, 1313-1317.	15.2	412
16	Molecular Evidence of Sexual Transmission of Ebola Virus. New England Journal of Medicine, 2015, 373, 2448-2454.	13.9	380
17	Middle East Respiratory Syndrome Coronavirus Infection in Dromedary Camels in Saudi Arabia. MBio, 2014, 5, e00884-14.	1.8	359
18	Next-generation vaccine platforms for COVID-19. Nature Materials, 2020, 19, 810-812.	13.3	276

#	Article	IF	CITATIONS
19	Middle East respiratory syndrome coronavirus (MERS-CoV) causes transient lower respiratory tract infection in rhesus macaques. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 16598-16603.	3.3	264
20	Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin. Scientific Reports, 2013, 3, 1686.	1.6	250
21	Replication and Shedding of MERS-CoV in Upper Respiratory Tract of Inoculated Dromedary Camels. Emerging Infectious Diseases, 2014, 20, 1999-2005.	2.0	233
22	K18-hACE2 mice develop respiratory disease resembling severe COVID-19. PLoS Pathogens, 2021, 17, e1009195.	2.1	227
23	Correction to Middle East Respiratory Syndrome Coronavirus Infection in Dromedary Camels in Saudi Arabia. MBio, 2014, 5, .	1.8	209
24	Effectiveness of N95 Respirator Decontamination and Reuse against SARS-CoV-2 Virus. Emerging Infectious Diseases, 2020, 26, 2253-2255.	2.0	200
25	Infection with MERS-CoV Causes Lethal Pneumonia in the Common Marmoset. PLoS Pathogens, 2014, 10, e1004250.	2.1	186
26	Nanopore Sequencing as a Rapidly Deployable Ebola Outbreak Tool. Emerging Infectious Diseases, 2016, 22, 331-4.	2.0	175
27	Efficient generation and growth of influenza virus A/PR/8/34 from eight cDNA fragments. Virus Research, 2004, 103, 155-161.	1.1	171
28	Remdesivir (GS-5734) protects African green monkeys from Nipah virus challenge. Science Translational Medicine, 2019, 11, .	5.8	166
29	Molecular Determinants of Adaptation of Highly Pathogenic Avian Influenza H7N7 Viruses to Efficient Replication in the Human Host. Journal of Virology, 2010, 84, 1597-1606.	1.5	148
30	<i>In Vitro</i> Assessment of Attachment Pattern and Replication Efficiency of H5N1 Influenza A Viruses with Altered Receptor Specificity. Journal of Virology, 2010, 84, 6825-6833.	1.5	146
31	Seasonal and Pandemic Human Influenza Viruses Attach Better to Human Upper Respiratory Tract Epithelium than Avian Influenza Viruses. American Journal of Pathology, 2010, 176, 1614-1618.	1.9	146
32	Single-cell RNA sequencing reveals SARS-CoV-2 infection dynamics in lungs of African green monkeys. Science Translational Medicine, 2021, 13, .	5.8	146
33	Replication and shedding of MERS-CoV in Jamaican fruit bats (Artibeus jamaicensis). Scientific Reports, 2016, 6, 21878.	1.6	138
34	Possible sexual transmission of Ebola virus - Liberia, 2015. Morbidity and Mortality Weekly Report, 2015, 64, 479-81.	9.0	132
35	The Molecular Basis of the Pathogenicity of the Dutch Highly Pathogenic Human Influenza A H7N7 Viruses. Journal of Infectious Diseases, 2007, 196, 258-265.	1.9	129
36	Mutation rate and genotype variation of Ebola virus from Mali case sequences. Science, 2015, 348, 117-119.	6.0	127

#	Article	IF	CITATIONS
37	Practical Considerations for High-Throughput Influenza A Virus Surveillance Studies of Wild Birds by Use of Molecular Diagnostic Tests. Journal of Clinical Microbiology, 2009, 47, 666-673.	1.8	126
38	Introduction of Virulence Markers in PB2 of Pandemic Swine-Origin Influenza Virus Does Not Result in Enhanced Virulence or Transmission. Journal of Virology, 2010, 84, 3752-3758.	1.5	126
39	Pneumonia from Human Coronavirus in a Macaque Model. New England Journal of Medicine, 2013, 368, 1560-1562.	13.9	126
40	Severity of Pneumonia Due to New H1N1 Influenza Virus in Ferrets Is Intermediate between That Due to Seasonal H1N1 Virus and Highly Pathogenic Avian Influenza H5N1 Virus. Journal of Infectious Diseases, 2010, 201, 993-999.	1.9	121
41	The Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Does Not Replicate in Syrian Hamsters. PLoS ONE, 2013, 8, e69127.	1.1	114
42	The vesicular stomatitis virus-based Ebola virus vaccine: From concept to clinical trials. Human Vaccines and Immunotherapeutics, 2018, 14, 2107-2113.	1.4	107
43	Microbial signatures in the lower airways of mechanically ventilated COVID-19 patients associated with poor clinical outcome. Nature Microbiology, 2021, 6, 1245-1258.	5.9	101
44	Mini viral RNAs act as innate immune agonists during influenza virus infection. Nature Microbiology, 2018, 3, 1234-1242.	5.9	96
45	Rapid Nipah virus entry into the central nervous system of hamsters via the olfactory route. Scientific Reports, 2012, 2, 736.	1.6	93
46	Functional Constraints of Influenza A Virus Epitopes Limit Escape from Cytotoxic T Lymphocytes. Journal of Virology, 2005, 79, 11239-11246.	1.5	89
47	Protective efficacy of a novel simian adenovirus vaccine against lethal MERS-CoV challenge in a transgenic human DPP4 mouse model. Npj Vaccines, 2017, 2, 28.	2.9	81
48	Role of the Pilot Protein YscW in the Biogenesis of the YscC Secretin in Yersinia enterocolitica. Journal of Bacteriology, 2004, 186, 5366-5375.	1.0	80
49	Protection of Mice against Lethal Infection with Highly Pathogenic H7N7 Influenza A Virus by Using a Recombinant Low-Pathogenicity Vaccine Strain. Journal of Virology, 2005, 79, 12401-12407.	1.5	76
50	Efficacy of an Adjuvanted Middle East Respiratory Syndrome Coronavirus Spike Protein Vaccine in Dromedary Camels and Alpacas. Viruses, 2019, 11, 212.	1.5	75
51	Insertion of a Multibasic Cleavage Motif into the Hemagglutinin of a Low-Pathogenic Avian Influenza H6N1 Virus Induces a Highly Pathogenic Phenotype. Journal of Virology, 2010, 84, 7953-7960.	1.5	73
52	Identification of Amino Acid Substitutions Supporting Antigenic Change of Influenza A(H1N1)pdm09 Viruses. Journal of Virology, 2015, 89, 3763-3775.	1.5	73
53	Emerging influenza. Journal of Clinical Virology, 2008, 41, 1-6.	1.6	72
54	Comparison of the Pathogenicity of Nipah Virus Isolates from Bangladesh and Malaysia in the Syrian Hamster. PLoS Neglected Tropical Diseases, 2013, 7, e2024.	1.3	71

#	Article	IF	CITATIONS
55	Fitness costs limit escape from cytotoxic T lymphocytes by influenza A viruses. Vaccine, 2006, 24, 6594-6596.	1.7	67
56	Yearlong COVID-19 Infection Reveals Within-Host Evolution of SARS-CoV-2 in a Patient With B-Cell Depletion. Journal of Infectious Diseases, 2022, 225, 1118-1123.	1.9	62
57	A reverse-genetics system for Influenza A virus using T7 RNA polymerase. Journal of General Virology, 2007, 88, 1281-1287.	1.3	61
58	Advances and gaps in SARS-CoV-2 infection models. PLoS Pathogens, 2022, 18, e1010161.	2.1	61
59	Animal models of disease shed light on Nipah virus pathogenesis and transmission. Journal of Pathology, 2015, 235, 196-205.	2.1	58
60	Foodborne Transmission of Nipah Virus in Syrian Hamsters. PLoS Pathogens, 2014, 10, e1004001.	2.1	56
61	Efficacy of antibody-based therapies against Middle East respiratory syndrome coronavirus (MERS-CoV) in common marmosets. Antiviral Research, 2017, 143, 30-37.	1.9	56
62	Outbreaks in a Rapidly Changing Central Africa — Lessons from Ebola. New England Journal of Medicine, 2018, 379, 1198-1201.	13.9	56
63	Nipah Virus Transmission in a Hamster Model. PLoS Neglected Tropical Diseases, 2011, 5, e1432.	1.3	55
64	ChAdOx1 nCoV-19 (AZD1222) protects Syrian hamsters against SARS-CoV-2 B.1.351 and B.1.1.7. Nature Communications, 2021, 12, 5868.	5.8	52
65	1918 H1N1 Influenza Virus Replicates and Induces Proinflammatory Cytokine Responses in Extrarespiratory Tissues of Ferrets. Journal of Infectious Diseases, 2018, 217, 1237-1246.	1.9	49
66	Pathogenicity of highly pathogenic avian influenza virus in mammals. Vaccine, 2008, 26, D54-D58.	1.7	48
67	Sustained fecal-oral human-to-human transmission following a zoonotic event. Current Opinion in Virology, 2017, 22, 1-6.	2.6	46
68	Emerging preclinical evidence does not support broad use of hydroxychloroquine in COVID-19 patients. Nature Communications, 2020, 11, 4253.	5.8	43
69	PlasmodiumParasitemia Associated With Increased Survival in Ebola Virus–Infected Patients. Clinical Infectious Diseases, 2016, 63, 1026-1033.	2.9	42
70	Transmission of henipaviruses. Current Opinion in Virology, 2018, 28, 7-11.	2.6	41
71	Pathogenicity and Viral Shedding of MERS-CoV in Immunocompromised Rhesus Macaques. Frontiers in Immunology, 2018, 9, 205.	2.2	41
72	Onward transmission of viruses: how do viruses emerge to cause epidemics after spillover?. Philosophical Transactions of the Royal Society B: Biological Sciences, 2019, 374, 20190017.	1.8	41

#	Article	IF	CITATIONS
73	Dromedary camels in northern Mali have high seropositivity to MERS-CoV. One Health, 2017, 3, 41-43.	1.5	37
74	An Acute Immune Response to Middle East Respiratory Syndrome Coronavirus Replication Contributes to Viral Pathogenicity. American Journal of Pathology, 2016, 186, 630-638.	1.9	35
75	Hydroxychloroquine prophylaxis and treatment is ineffective in macaque and hamster SARS-CoV-2 disease models. JCI Insight, 2020, 5, .	2.3	35
76	Pandemic 2009 H1N1 Influenza Virus Causes Diffuse Alveolar Damage in Cynomolgus Macaques. Veterinary Pathology, 2010, 47, 1040-1047.	0.8	34
77	Antiviral agents for the treatment of COVID-19: Progress and challenges. Cell Reports Medicine, 2022, 3, 100549.	3.3	33
78	Insertion of a multibasic cleavage site in the haemagglutinin of human influenza H3N2 virus does not increase pathogenicity in ferrets. Journal of General Virology, 2011, 92, 1410-1415.	1.3	32
79	Syrian Hamsters ( <i>Mesocricetus auratus</i> ) Oronasally Inoculated With a Nipah Virus Isolate From Bangladesh or Malaysia Develop Similar Respiratory Tract Lesions. Veterinary Pathology, 2015, 52, 38-45.	0.8	32
80	Dose–response and transmission: the nexus between reservoir hosts, environment and recipient hosts. Philosophical Transactions of the Royal Society B: Biological Sciences, 2019, 374, 20190016.	1.8	30
81	Evidence for specific packaging of the influenza A virus genome from conditionally defective virus particles lacking a polymerase gene. Vaccine, 2006, 24, 6647-6650.	1.7	29
82	Safety of Recombinant VSV–Ebola Virus Vaccine Vector in Pigs. Emerging Infectious Diseases, 2015, 21, 702-704.	2.0	27
83	A Comparative Review of Animal Models of Middle East Respiratory Syndrome Coronavirus Infection. Veterinary Pathology, 2016, 53, 521-531.	0.8	27
84	Prophylactic and therapeutic efficacy of mAb treatment against MERS-CoV in common marmosets. Antiviral Research, 2018, 156, 64-71.	1.9	26
85	The Merits of Malaria Diagnostics during an Ebola Virus Disease Outbreak. Emerging Infectious Diseases, 2016, 22, 323-6.	2.0	25
86	Prior aerosol infection with lineage A SARS-CoV-2 variant protects hamsters from disease, but not reinfection with B.1.351 SARS-CoV-2 variant. Emerging Microbes and Infections, 2021, 10, 1284-1292.	3.0	25
87	Rapid sequencing of the non-coding regions of influenza A virus. Journal of Virological Methods, 2007, 139, 85-89.	1.0	24
88	Ebola Laboratory Response at the Eternal Love Winning Africa Campus, Monrovia, Liberia, 2014–2015. Journal of Infectious Diseases, 2016, 214, S169-S176.	1.9	24
89	Subtle differences in the pathogenicity of SARS-CoV-2 variants of concern B.1.1.7 and B.1.351 in rhesus macaques. Science Advances, 2021, 7, eabj3627.	4.7	24
90	Influenza Virus A/Anhui/1/2013 (H7N9) Replicates Efficiently in the Upper and Lower Respiratory Tracts of Cynomolgus Macaques. MBio, 2014, 5, .	1.8	23

#	Article	IF	CITATIONS
91	Identifying Early Target Cells of Nipah Virus Infection in Syrian Hamsters. PLoS Neglected Tropical Diseases, 2016, 10, e0005120.	1.3	23
92	Assessment of Rodents as Animal Models for Reston Ebolavirus. Journal of Infectious Diseases, 2011, 204, S968-S972.	1.9	22
93	Disruption of the Golgi Apparatus and Contribution of the Endoplasmic Reticulum to the SARS-CoV-2 Replication Complex. Viruses, 2021, 13, 1798.	1.5	22
94	Nipah@20: Lessons Learned from Another Virus with Pandemic Potential. MSphere, 2020, 5, .	1.3	21
95	Tackling Ebola: new insights into prophylactic and therapeutic intervention strategies. Genome Medicine, 2011, 3, 5.	3.6	20
96	The immune response to Nipah virus infection. Archives of Virology, 2012, 157, 1635-1641.	0.9	19
97	Histologic pulmonary lesions of SARS-CoV-2 in 4 nonhuman primate species: An institutional comparative review. Veterinary Pathology, 2022, 59, 673-680.	0.8	19
98	Domestic Pig Unlikely Reservoir for MERS-CoV. Emerging Infectious Diseases, 2017, 23, 985-988.	2.0	18
99	Age-related differences in immune dynamics during SARS-CoV-2 infection in rhesus macaques. Life Science Alliance, 2022, 5, e202101314.	1.3	18
100	Mild SARS-CoV-2 infection in rhesus macaques is associated with viral control prior to antigen-specific T cell responses in tissues. Science Immunology, 2022, 7, eabo0535.	5.6	17
101	MERS-CoV: the intermediate host identified?. Lancet Infectious Diseases, The, 2013, 13, 827-828.	4.6	16
102	Reston virus causes severe respiratory disease in young domestic pigs. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	16
103	Twenty Years of Nipah Virus Research: Where Do We Go From Here?. Journal of Infectious Diseases, 2020, 221, S359-S362.	1.9	15
104	Prophylactic efficacy of a human monoclonal antibody against MERS-CoV in the common marmoset. Antiviral Research, 2019, 163, 70-74.	1.9	8
105	Clinical Chemistry of Patients With Ebola in Monrovia, Liberia. Journal of Infectious Diseases, 2016, 214, S303-S307.	1.9	7
106	A Novel Field-Deployable Method for Sequencing and Analyses of Henipavirus Genomes From Complex Samples on the MinION Platform. Journal of Infectious Diseases, 2020, 221, S383-S388.	1.9	5
107	Evaluation of viral load in patients with Ebola virus disease in Liberia: a retrospective observational study. Lancet Microbe, The, 2022, 3, e533-e542.	3.4	4
108	Birth and Pathogenesis of Rogue Respiratory Viruses. Annual Review of Pathology: Mechanisms of Disease, 2015, 10, 449-471.	9.6	3

#	Article	IF	CITATIONS
109	The Effect of Plasmodium on the Outcome of Ebola Virus Infection in a Mouse Model. Journal of Infectious Diseases, 2018, 218, S434-S437.	1.9	3
110	Subcutaneous remdesivir administration prevents interstitial pneumonia in rhesus macaques inoculated with SARS-CoV-2. Antiviral Research, 2022, 198, 105246.	1.9	2
111	Reply to Colebunders. Clinical Infectious Diseases, 2017, 64, 232.2-232.	2.9	0